Dominican company based in Santo Domingo · We only ship within the Dominican Republic · No international shippingDominican Republic only · No international shipping
ES Home Catalog Education COAs Calculator Founder
Tesamorelin
Renova Verification
  • ✓98.59% purity by HPLC + mass spectrometry
  • ✓Independent Janoshik 3rd-party analysis
  • ✓−20°C lyophilized · 2–8°C reconstituted
🧪 View COA →
Home › Products › Growth Hormone › Tesamorelin
← Back to catalog Growth HormoneAvailable

Tesamorelin (10 mg)

US$240 (10 mg / vial, lyophilized). Delivery in 2–4 business hours in Santo Domingo at no charge; rest of the Dominican Republic in 6–12 h (RD$400). Janoshik COA linked below. Research use only.

GHRHVisceral fatFDA approved
$240 USD10 mg/vial
🧪 Bacteriostatic water — needed to reconstitute the lyophilized vial
💰 Buy by volume
3+ of one
Save 15%
5+ of one
Save 25%
★ Wholesale
10+ of one
Save 40%
🔀 Mix & Match · across different products: 3+ items 10% · 5+ 15% · 7+ 20%
The best discount per product is applied automatically at checkout (they don't stack). Excludes bacteriostatic water; Retatrutide and Tirzepatide only get same-product volume. Can't be combined with promo codes.
🧪 COA❄️ Cold chain🛡️ Replacement guarantee🔒 Secure payment📦 Nationwide shipping🇺🇸 cGMP · ISO 9001 guidelines · COA

FDA-approved synthetic GHRH analog — the only peptide with specific indication for visceral abdominal fat reduction.

  • Mechanism: Stabilized GHRH analog; pulsatile GH secretion. GHRH receptor known.
  • Evidence: Strong human evidence (Phase 3) for HIV lipodystrophy; reduces visceral fat.
  • In context: FDA-approved (Egrifta). Renova supplies it for research only. GH/IGF-1 pro-growth; may affect glucose.
Research range · SC
1.4–2 mg per application · once daily
🟢 Clinical evidence

Ranges cited in research literature. Not a usage recommendation. For research use only.

📋 Technical datasheet · Compound specifications
CompoundTesamorelin
Origin🇺🇸 From US-based suppliers that follow strict cGMP & ISO 9001 guidelines
FormLyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formulaC221H366N72O67S
Molecular weight5135.85 g/mol
SequenceGHRH(1-44) + hexenoyl
Purity98.59% by HPLC + mass spectrometry (Janoshik Analytical)
StorageLyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C · stability varies by peptide (see the reconstitution guide and the product COA)
Recommended solventBacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain2–8°C in transit · controlled thermal packaging
UseResearch Use Only (RUO). Not intended for human or veterinary use.

Typical values for this compound category. For product-specific data, see the corresponding COA at /en/coa/.

This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.

Tesamorelin: research profile

Tesamorelin is a synthetic analog of full-length human GHRH, all 44 amino acids, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. That small hydrophobic modification blocks the DPP-4 cleavage that inactivates natural GHRH within minutes, and it is the reason tesamorelin has a 25-to-40-minute half-life and more sustained activity than sermorelin. It was developed by Theratechnologies (Montreal).

Like all GHRH analogs it stimulates pulsatile GH secretion through its pituitary receptor and raises IGF-1 in a manner dependent on an intact axis. What sets it apart is its clinical base: two Phase 3 trials in more than 800 people with HIV and abdominal fat accumulation showed a CT-measured reduction in visceral adipose tissue of around 15–18% at 26 weeks, reversing on discontinuation (Falutz et al., NEJM 2007 and JCEM 2010). A later trial described a reduction in liver fat in the same population (Stanley et al., Lancet HIV 2019).

On that evidence the FDA approved the molecule in 2010 as Egrifta, with the specific indication of reducing excess abdominal fat in HIV-associated lipodystrophy; it is not approved for any other use. The drug label records IGF-1 elevation, glucose disturbances, fluid retention and arthralgia, and contraindicates it in pregnancy and active malignancy. The product Renova distributes is not Egrifta: it is tesamorelin for research, independently verified and not suitable for human use.

Tesamorelin technical data

ClassStabilized GHRH(1-44) analog
StructureHuman GHRH(1-44)-NH2 with a trans-3-hexenoyl group on Tyr1 (44 aa)
CAS218949-48-5
Reported half-life≈ 25–40 minutes (DPP-4 resistant)
Phase 3 dataVisceral adipose tissue reduced ≈ 15–18% at 26 weeks in HIV lipodystrophy (NEJM 2007; JCEM 2010)
Regulatory statusMolecule FDA-approved as Egrifta (2010) for HIV lipodystrophy; Renova product is RUO
Drug-label considerationsIGF-1 elevation, glucose, fluid retention; contraindicated in pregnancy and active malignancy
StabilityLyophilized powder stable when cold; reconstituted solution must stay refrigerated

Questions about Tesamorelin

What distinguishes tesamorelin from natural GHRH?

A hexenoyl group at the N-terminus. Natural GHRH is inactivated by the DPP-4 enzyme within minutes; that modification blocks the cut and multiplies the molecule's duration. The 44-amino-acid sequence is the same as the human hormone's.

What is tesamorelin approved for?

As Egrifta, the FDA approved it in 2010 solely to reduce excess abdominal fat in people with HIV and lipodystrophy. It holds no approval for any other indication. Renova's material is for research and is not that medicine.

What did the tesamorelin Phase 3 trials show?

In two trials with more than 800 participants with HIV, CT-measured visceral adipose tissue fell by about 15–18% at 26 weeks versus placebo, with no relevant change in subcutaneous fat; the effect reversed when treatment stopped. A 2019 trial additionally described a reduction in liver fat in that population.

Tesamorelin or sermorelin?

Two GHRH analogs with different duration: sermorelin is the native 1-29 fragment and lasts 10–20 minutes; tesamorelin is the stabilized full sequence and lasts more than twice as long, with Phase 3 clinical backing. Our guide on tesamorelin and visceral fat details the differences.

Related reading: Tesamorelin: GHRH Analog and Visceral Fat · CJC-1295 + Ipamorelin: The Most-Studied GH Stack

Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.

Questions? Write us

Your Order

Your cart is empty